A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00918203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
Study identification
- NCT ID
- NCT00918203
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2009
- Primary completion
- Jul 31, 2013
- Completion
- Nov 16, 2017
- Last update posted
- Jan 9, 2019
2010 – 2017
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Birmingham | Alabama | 35294 | — |
| ImClone Investigational Site | Bakersfield | California | 93309 | — |
| ImClone Investigational Site | Highland | California | 92346 | — |
| ImClone Investigational Site | Stamford | Connecticut | 06902 | — |
| ImClone Investigational Site | Port Saint Lucie | Florida | 34952 | — |
| ImClone Investigational Site | Joliet | Illinois | 60435 | — |
| ImClone Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| ImClone Investigational Site | St Louis | Missouri | 63110 | — |
| ImClone Investigational Site | Charlotte | North Carolina | 28203 | — |
| ImClone Investigational Site | Gastonia | North Carolina | 20854 | — |
| ImClone Investigational Site | Huntersville | North Carolina | 28078 | — |
| ImClone Investigational Site | Canton | Ohio | 44708 | — |
| ImClone Investigational Site | Cleveland | Ohio | 44106 | — |
| ImClone Investigational Site | Cleveland | Ohio | 44195 | — |
| ImClone Investigational Site | Massillon | Ohio | 44646 | — |
| ImClone Investigational Site | Portland | Oregon | 97239 | — |
| ImClone Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| ImClone Investigational Site | Dallas | Texas | 75390-8852 | — |
| ImClone Investigational Site | Round Rock | Texas | 78665 | — |
| ImClone Investigational Site | Temple | Texas | 76508 | — |
| ImClone Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00918203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2019 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00918203 live on ClinicalTrials.gov.